Get In Touch

Growing prevalence of chronic respiratory diseases is one of the key factors anticipated to accelerate demand for pulmonary drug delivery systems (PDDS) in coming years.

As per a report published by the Global Asthma Network (GAN), in 2014, 334 million cases has been diagnosed across the globe. Growing incidence of respiratory diseases has resulted in increase in patient population. This, in turn, has resulted in increase in fuelled demand for pulmonary drug delivery devices. Subsequently, growing demand rate is boosting the global pulmonary drug delivery devices market.

Further, technological advancements in the field is projected to provide lucrative opportunities for expansion of the market.

Meanwhile, drawback of conventional treatment methods such as low efficacy and late onset of action is the key development areas. Research and development activities aiming to develop novel targeted drug delivery devices is likely to provide new growth avenues for widening of the pulmonary drug delivery devices market in coming years.

At the same time, growing number of initiatives undertaken by government bodies and non-government organizations is, further, contributing to the market growth in terms of revenue. For example, CDC’s National Asthma Control Program (NACP) is allotting funds for raising awareness regarding asthma among people as well as the affected patients.

Rising awareness regarding asthma is expected to boost the adoption rate of pulmonary drug delivery devices for treatment of the asthma and Chronic Obstructive Pulmonary Diseases (COPD). This, in turn, result in growth of the global market.

North America Market is anticipated to lead in the global pulmonary drug delivery devices market in coming years. Prominence of the region is attributed to increasing cases of affected people and growing demand for diagnostic devices.

  • According to Transparency Market Research’s latest report on the global pulmonary drug delivery devices market for the historical period 2017–2018 and forecast period 2019–2027, ‘increase in the prevalence and incidence of respiratory diseases across globe, increasing population of smokers across countries, rising prescription of the combination therapies, and rising research & development in the asthma & COPD treatment’ are projected to drive the global pulmonary drug delivery devices market.
  • According to the report, the global pulmonary drug delivery devices market was valued at US$ 36,159.9 Mn in 2018 and is projected to expand at a CAGR of 2.7% from 2019 to 2027.

To know the scope of our report Get a Sample on Pulmonary Drug Delivery Devices Market

Increase in prevalence and incidence of respiratory diseases: Key Drivers

  • Chronic obstructive pulmonary disease (COPD) is an umbrella term used to describe various progressive lung diseases such as emphysema, chronic bronchitis, refractory asthma, and others. Patients suffering from severe COPD require continuous supply of oxygen. Often symptoms such as increased breathlessness and coughing are ignored as a normal sign of aging; however, these are the early signs of COPD. According to WHO, COPD is the fourth-leading cause of death globally, with approximately 2.75 million deaths per annum. According to the CDC, over 16 million people in the U.S. are living with respiratory disorders, such as lung cancer, COPD, and heart diseases, caused due to smoking. Around 100 million adults are estimated to be suffering from COPD indication, and these statistics are expected to drive the pulmonary drug delivery devices market.
  • According to the United Nations, the geriatric population of people above the age of 60 is expected to double by 2050, and triple by 2100, which means that it is projected to rise from 962 million in 2017 to 2.1 billion in 2050 and reach 3.1 billion by 2100. Globally, the geriatric population is increasing at a faster pace than that of the younger age group, the present geriatric population of 962 million is about 13% of the global population and is increasing at a rate of about 3% every year. Furthermore, the number of persons age 80 years or above is estimated to be triple by 2050, an increase from 137 million in 2017 to 425 million by 2050.
  • The number of smokers is also increasing globally. The U.S. has seen a decline in the percentage of people smoking; however, there are still 40 million adults who smoke and 20 million will die prematurely unless they quit. Also, exposure to secondhand smoke raises complications for people suffering from asthma and COPD. According to the American Lung Association, exposure to secondhand smoke can cause more than 202,000 asthma flare-ups among children each year.

Get a glimpse of the in-depth analysis through our Report Brochure

Low Cost Generic Competition Likely To Hamper Market: Key Restraint

  • Patent loss of branded drugs in the pulmo0nary drug delivery devices market provides a platform for the entry of generic drugs. Generics are generally priced lower than their equivalent branded drugs which attract large number of patients in low- and middle-income countries where the prevalence of pulmonary diseases is high as per the data provided by WHO, thus increase in generic drugs in the pulmonary drug delivery devices market will lead to decline in revenues. Moreover, patent loss of drugs such as Advair Diskus (GSK) during the forecast period will hit the market drastically and increase competitive scenario in the generic as well as branded drugs market.

Global Pulmonary drug delivery devices Market: Competitive Landscape

  • This report profiles major players in the global Pulmonary drug delivery devices market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global pulmonary drug delivery devices market is fragmented, with the presence of a number of international, regional players as well as local players. Various players operating in the global pulmonary drug delivery devices market are
    • Boehringer Ingelheim GmbH
    • Novartis AG
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Teva Pharmaceutical Industries Ltd
    •  Merck & Co., Inc
    •  MannKind Corporation,
    • F. Hoffmann-La Roche Ltd.
    • Mylan N.V.
    • Omron Corporation
    • 3M Healthcare
    • Sunovion Pharmaceuticals, Inc
    • Koninklijke Philips N.V.
    • PARI GmbH
    • Nypro Healthcare Inc. (Jabil Circuit Inc.)
  • other prominent players.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Pulmonary drug delivery devices Market: Key Developments

Key players in the global pulmonary drug delivery devices market are engaged in geographic expansion through merger & acquisitions, innovation and reimbursement scenarios, research & development, technological advancements, and launch of new products. These strategies of key players are likely to fuel the growth of the global pulmonary drug delivery devices market. A few strong strategies adopted by players operating in the global pulmonary drug delivery devices market are:

  • In February 2020, Teva Pharmaceuticals received USFDA approval of its ArmonAir Digihaler Inhalation powder, an inhaled corticosteroid delivered through Digihaler device to the Asthma patients.
  • In December 2018, FDA approved Teva pharmaceutical’s ProAir Digihaler device, a digital inhaler which utilizes sensors and mobile app for people suffering from asthma and chronic obstructive pulmonary disease.
  •  In April 2018, Sunovion Pharmaceuticals launched in Lonhala Magnair drug in the United States for the long term maintenance of the airflow obstruction in the chronic obstructive pulmonary disease (COPD) patients. This is the first nebulized long-acting muscarinic antagonist approved for the treatment of the COPD condition in the United States.
  • On October 2016, AstraZeneca entered into an agreement with’ Cilag GmbH International’, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua (nasal spray indicated for allergic and non-allergic rhinitis) outside the US.

The report on the global pulmonary drug delivery devices market discussed individual strategies, followed by company profiles of manufacturers of drug delivery systems for managing pulmonary condition. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global pulmonary drug delivery devices market.

TMR’s report on the global pulmonary drug delivery devices market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators of the Market during the forecast period from 2019 to 2027. The report provides revenue of the global pulmonary drug delivery devices market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global pulmonary drug delivery devices market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global pulmonary drug delivery devices market.

Secondary research also included Internet sources, statistical data from government agencies, websites, companies’ presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global pulmonary drug delivery devices market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global pulmonary drug delivery devices market.  These indices serve as valuable tools for existing market players as well as for entities interested in entering the global pulmonary drug delivery devices market.

The report delves into the competitive landscape of the global pulmonary drug delivery devices market. Key players operating in the global pulmonary drug delivery devices market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global pulmonary drug delivery devices market that have been profiled in this report.

Key Questions Answered in Global Pulmonary Drug Delivery Devices Market Report

  • What is the scope of growth of product companies in the global pulmonary drug delivery devices Market?
  • What will be the Y-o-Y growth of the global pulmonary drug delivery devices market between 2019 and 2027?
  • What is the influence of growing disease prevalence on the global pulmonary drug delivery devices market?
  • What are the technological advancements for the treatment of the pulmonary drug delivery devices condition?
  • Which region continue to be the most profitable market for pulmonary drug delivery devices market?
  • Which factors are anticipated to hamper the growth of the global pulmonary drug delivery devices market during the forecast period?
  • Which are the leading companies in the global pulmonary drug delivery devices market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global pulmonary drug delivery devices market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global pulmonary drug delivery devices market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and Market intelligence managers, who contributed to the production of TMR’s study on the pulmonary drug delivery devices market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serve as a validation from the pulmonary drug delivery devices market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global pulmonary drug delivery devices market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global pulmonary drug delivery devices market more reliably and accurately.

Regional Segmentation of Global Pulmonary Drug Delivery Devices Market   

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Global Pulmonary Drug Delivery Devices Market - Segmentation

Product

Dry Powder Inhaler

Metered Dose Inhaler

Nebulizers

Application

Cystic Fibrosis

Others

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

E-commerce

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pulmonary Drug Delivery Devices Market  

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter Five Forces Analysis

5. Key Insights

    5.1. Disease Prevalence across Region/Globally

    5.2.  Pipeline Analysis 

    5.3. Technological Advancements

6. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Product    

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Product  , 2017–2027

        6.2.1. Dry Powder Inhaler

        6.2.2. Metered Dose Inhaler

        6.2.3. Nebulizers

    6.3. Global Pulmonary Drug Delivery Devices Market  Attractiveness, by Product   

7. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Application

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        7.2.1. Asthma

        7.2.2. COPD

        7.2.3. Cystic fibrosis

        7.2.4. Others

8. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Distribution Channel 

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Distribution Channel , 2017–2027

        8.2.1. Hospital Pharmacies     

        8.2.2. Retail Pharmacies   

        8.2.3. E-commerce 

    8.3. Global Pulmonary Drug Delivery Devices Market   Attractiveness, by Distribution Channel   

9. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Global  Pulmonary Drug Delivery Devices Market   Attractiveness, by Region

10. North America Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        10.2.1. Dry Powder Inhaler

        10.2.2. Metered Dose Inhaler

        10.2.3. Nebulizers

    10.3. North America Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        10.3.1. Asthma

        10.3.2. COPD

        10.3.3. Cystic fibrosis

        10.3.4. Others

    10.4. North America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        10.4.1. Hospital Pharmacies     

        10.4.2. Retail Pharmacies   

        10.4.3. E-commerce  

    10.5. North America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        10.6.1. By Product    

        10.6.2. Application

        10.6.3. By Distribution Channel   

        10.6.4. By Country

11. Europe Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        11.2.1. Dry Powder Inhaler

        11.2.2. Metered Dose Inhaler

        11.2.3. Nebulizers 

    11.3. Europe Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        11.3.1. Asthma

        11.3.2. COPD

        11.3.3. Cystic fibrosis

        11.3.4. Others

    11.4. Europe Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        11.4.1. Hospital Pharmacies     

        11.4.2. Retail Pharmacies   

        11.4.3. E-commerce  

    11.5. Europe Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe 

    11.6. Europe Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        11.6.1. By Product   

        11.6.2. Application

        11.6.3. By Distribution Channel   

        11.6.4. By Country/Sub-region

12. Asia Pacific Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        12.2.1. Dry Powder Inhaler

        12.2.2. Metered Dose Inhaler

        12.2.3. Nebulizers

    12.3. Asia Pacific Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        12.3.1. Asthma

        12.3.2. COPD

        12.3.3. Cystic fibrosis

        12.3.4. Others

    12.4. Asia Pacific Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        12.4.1. Hospital Pharmacies     

        12.4.2. Retail Pharmacies   

        12.4.3. E-commerce  

    12.5. Asia Pacific Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific 

    12.6. Asia Pacific Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        12.6.1. By Product   

        12.6.2. Application

        12.6.3. By Distribution Channel   

        12.6.4. By Country/Sub-region

13. Latin America Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        13.2.1. Dry Powder Inhaler

        13.2.2. Metered Dose Inhaler

        13.2.3. Nebulizers

    13.3. Latin America Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        13.3.1. Asthma

        13.3.2. COPD

        13.3.3. Cystic fibrosis

        13.3.4. Others

    13.4. Latin America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        13.4.1. Hospital Pharmacies     

        13.4.2. Retail Pharmacies   

        13.4.3. E-commerce  

    13.5. Latin America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America 

    13.6. Latin America Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        13.6.1. By Product   

        13.6.2. Application

        13.6.3. By Distribution Channel   

        13.6.4. By Country/Sub-region

14. Middle East & Africa Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        14.2.1. Dry Powder Inhaler

        14.2.2. Metered Dose Inhaler

        14.2.3. Nebulizers 

    14.3. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        14.3.1. Asthma

        14.3.2. COPD

        14.3.3. Cystic fibrosis

        14.3.4. Others

    14.4. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        14.4.1. Hospital Pharmacies     

        14.4.2. Retail Pharmacies   

        14.4.3. E-commerce  

    14.5. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa 

    14.6. Middle East & Africa Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        14.6.1. By Product   

        14.6.2. Application

        14.6.3. By Distribution Channel   

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Share Analysis

    15.2. Company Profiles

        15.2.1. 3M

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview 

            15.2.1.3. Growth Strategies

            15.2.1.4. SWOT Analysis

        15.2.2. BMG Pharma 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Growth Strategies

            15.2.2.3. SWOT Analysis

        15.2.3. ConvaTec Inc

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Financial Overview 

            15.2.3.3. Growth Strategies

            15.2.3.4. SWOT Analysis

        15.2.4. Integra Life Sciences

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Financial Overview 

            15.2.4.3. Growth Strategies

            15.2.4.4. SWOT Analysis

        15.2.5. Intermed Pharmaceuticals

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Financial Overview 

            15.2.5.3. Growth Strategies

            15.2.5.4. SWOT Analysis

        15.2.6. Molnlycke Health Care AB

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Financial Overview 

            15.2.6.3. Growth Strategies

            15.2.6.4. SWOT Analysis

        15.2.7. Smith & Nephew 

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Financial Overview 

            15.2.7.3. Growth Strategies

            15.2.7.4. SWOT Analysis

        15.2.8. Stratpharma AG

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Growth Strategies

            15.2.8.3. SWOT Analysis

List of Tables

Table 01: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 01: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 03: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 06: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 07: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 08: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 10: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 11: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 14: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 15: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 18: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 19: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 20: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 21: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 22: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 23: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 01: Global Pulmonary Drug Delivery Devices Market  Snapshot

Figure 02: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 03: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast, 2017?2027

Figure 04: Global Pulmonary Drug Delivery Devices Market Value Share, by Product   , 2018

Figure 05: Global Pulmonary Drug Delivery Devices Market Value Share, by Application   , 2018

Figure 06: Global Pulmonary Drug Delivery Devices Market Value Share, by Distribution Channel    2018

Figure 07: Global Pulmonary Drug Delivery Devices Market Value Share, by Region, 2018

Figure 08: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product   , 2018 and 2027

Figure 09: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dry Powder Inhaler, 2017–2027

Figure 10: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Metered Dose Inhaler, 2017–2027

Figure 11: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nebulizers, 2017–2027

Figure 12: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Distribution Channel,  2018 and 2027

Figure 13: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies , 2017–2027

Figure 14: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies   , 2017–2027

Figure 15: Global Pulmonary Drug Delivery Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by E-commerce , 2017–2027

Figure 16: Global Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Distribution Channel    2019–2027

Figure 17: Global Pulmonary Drug Delivery Devices Market  Snapshot, by Country/Sub-region

Figure 18: Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Region 2018 and 2027

Figure 19: Global Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Region, 2019–2027

Figure 20: North America Pulmonary Drug Delivery Devices Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 21: North America Pulmonary Drug Delivery Devices Market Value Share (%), by Product   , 2018 and 2027

Figure 22: North America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Product   , 2019–2027

Figure 23: North America Pulmonary Drug Delivery Devices Market Value Share (%), by Application , 2018 and 2027

Figure 24: North America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Application, 2019–2027

Figure 25: North America Pulmonary Drug Delivery Devices Market Value Share (%), by Distribution Channel    2018 and 2027

Figure 26: North America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Distribution Channel    2019–2027

Figure 27: North America Pulmonary Drug Delivery Devices Market Value Share (%), by Country/ Sub-region, 2018 and 2027

Figure 28: North America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Country/ Sub-region, 2019–2027

Figure 29: Europe Pulmonary Drug Delivery Devices Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 30: Europe Pulmonary Drug Delivery Devices Market Value Share (%), by Product   , 2018 and 2027

Figure 31: Europe Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Product   , 2019–2027

Figure 32: Europe Pulmonary Drug Delivery Devices Market Value Share (%), by Application , 2018 and 2027

Figure 33: Europe Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Application, 2019–2027

Figure 34: Europe Pulmonary Drug Delivery Devices Market Value Share (%), by Distribution Channel    2018 and 2027

Figure 35: Europe Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Distribution Channel    2019–2027

Figure 36: Europe Pulmonary Drug Delivery Devices Market Value Share (%), by Country/Sub-region, 2018 and 2027

Figure 37: Europe Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Country/Sub-region, 2019–2027

Figure 38: Asia Pacific Pulmonary Drug Delivery Devices Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 39: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share (%), by Product  , 2018 and 2027

Figure 40: Asia Pacific Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Product   , 2019–2027

Figure 41: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share (%), by Application , 2018 and 2027

Figure 42: Asia Pacific Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Application, 2019–2027

Figure 43: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share (%), by Distribution Channel    2018 and 2027

Figure 44: Asia Pacific Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Distribution Channel    2019–2027

Figure 45: Asia Pacific Pulmonary Drug Delivery Devices Market Value Share (%), by Country/Sub-region, 2018 and 2027

Figure 46: Asia Pacific Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Country/Sub-region, 2019–2027

Figure 47: Latin America Pulmonary Drug Delivery Devices Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 48: Latin America Pulmonary Drug Delivery Devices Market Value Share (%), by Product  , 2018 and 2027

Figure 49: Latin America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Product , 2019–2027

Figure 50: Latin America Pulmonary Drug Delivery Devices Market Value Share (%), by Application , 2018 and 2027

Figure 51: Latin America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Application, 2019–2027

Figure 52: Latin America Pulmonary Drug Delivery Devices Market Value Share (%), by Distribution Channel  2018 and 2027

Figure 53: Latin America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Distribution Channel    2019–2027

Figure 54: Latin America Pulmonary Drug Delivery Devices Market Value Share (%), by Country/Sub-region, 2018 and 2027

Figure 55: Latin America Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Country/Sub-region, 2019–2027

Figure 56: Middle East & Africa Pulmonary Drug Delivery Devices Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 57: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share (%), by Product   , 2018 and 2027

Figure 58: Middle East & Africa Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Product   , 2019–2027

Figure 59: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share (%), by Application , 2018 and 2027

Figure 60: Middle East & Africa Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Application, 2019–2027

Figure 61: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share (%), by Distribution Channel    2018 and 2027

Figure 62: Middle East & Africa Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Distribution Channel    2019–2027

Figure 63: Middle East & Africa Pulmonary Drug Delivery Devices Market Value Share (%), by Country/Sub-region, 2018 and 2027

Figure 64: Middle East & Africa Pulmonary Drug Delivery Devices Market  Attractiveness Analysis , by Country/Sub-region, 2019–2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Pulmonary Drug Delivery Devices Market 2018 2026